Emmaus Life Sciences, INC
Market Movers (8-K)
OQB
Emmaus Life Sciences reports an 18% decline in Q1 2026 revenue as generic competition impacts U.S. sales.
Worse than expected
Capital raise
OQB
Emmaus Life Sciences, Inc. has appointed Henry H. Du to its Board of Directors to fill the vacancy left by Jon Kuwahara.
OQB
Emmaus Life Sciences, Inc. announced the resignation of director Jon Kuwahara, effective April 15, 2026.
OQB
Emmaus Life Sciences announced a 25% drop in 2025 net revenues to $12.5 million, primarily due to generic competition, despite achieving income from operations.
Capital raise
Worse than expected
OQB
Emmaus Life Sciences entered an exclusive supply agreement with NeoImmuneTech for Endari in the U.S. and Canada, contingent on regulatory approvals.
OQB
Emmaus Life Sciences has granted NeoImmuneTech an exclusive license to market and distribute Endari for sickle cell disease in North America, receiving an upfront payment and royalties.
Worse than expected
Quarterly Earnings (10-Q)
OQB
Emmaus Life Sciences reports a Q1 2026 net loss of $3.3 million amid ongoing liquidity challenges and a transition to a new distribution model for Endari.
Worse than expected
Capital raise
OQB
Emmaus Life Sciences reported a significant revenue drop and increased net loss for Q3 2025, raising substantial doubt about its ability to continue as a going concern amidst generic competition.
Capital raise
Worse than expected
OQB
Emmaus Life Sciences reported a significant revenue decline and continued financial distress in its latest quarterly filing, citing generic competition as a primary factor.
Capital raise
Worse than expected
OQB
Emmaus Life Sciences experienced a slight decrease in net revenues for Q1 2025, primarily due to increased competition from a generic version of their sickle cell disease treatment, Endari, in the U.S. market.
Capital raise
Worse than expected
OQB
Emmaus Life Sciences experienced a revenue increase in Q3 2024 compared to Q3 2023, but faces challenges due to the expiration of Endari's exclusivity and the entry of generic competition.
Worse than expected
Capital raise
OQB
10-Q: Emmaus Life Sciences Reports Mixed Q2 Results Amidst Supply Chain Issues and Generic Competition
Emmaus Life Sciences experienced a significant decrease in revenue for the second quarter of 2024 due to supply chain disruptions and the launch of a generic competitor, while also reporting a net loss.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
OQB
10-K: Emmaus Life Sciences Reports FY2024 Results, Cites Revenue Decline and Going Concern Uncertainty
Emmaus Life Sciences' 10-K filing reveals a significant revenue drop in 2024 and raises substantial doubt about the company's ability to continue as a going concern.
Delay expected
Capital raise
Worse than expected
OQB
Emmaus Life Sciences secures a short-term $700,000 loan with a high interest rate, while also facing ongoing financial reporting issues and material weaknesses in internal controls.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
OQB
Director Lim Seah H. of Emmaus Life Sciences, Inc. reports purchasing 20,000 shares of common stock at $0.04 per share on September 16, 2024.
OQB
Willis C. Lee, Co-President & COO of Emmaus Life Sciences, Inc., has increased his indirect holdings of common stock through purchases made via his Fidelity Roth IRA.
Schedule 13G - Passive Investments
OQB
SCHEDULE 13G/A: Dr. Seah H. Lim Amends Significant Stake in Emmaus Life Sciences, Holding 6.5% of Common Stock
Dr. Seah H. Lim has filed an amended Schedule 13G, disclosing a beneficial ownership of 4,147,426 shares, representing 6.5% of Emmaus Life Sciences, Inc.'s common stock as of December 31, 2024.